Meningococcal Vaccines Market To Reach $5.96 Billion By 2033

Meningococcal Vaccines Market Growth & Trends

The global meningococcal vaccines market size is estimated to reach USD 5.96 billion by 2033, registering a CAGR of 4.5% from 2026 to 2033, according to a new report by Grand View Research, Inc. Increasing prevalence of meningitis is one of the major factors attributed to the market growth. For instance, according to ECDC, it was estimated that in 2017, 3,221 confirmed cases were observed in EU member states, wherein 58% cases were found in the U.K., France, Spain, and Germany. Moreover, a high incidence of meningitis disease is found in the “meningitis belt” of sub-Saharan Africa, and approximately 30,000 cases are reported every year in this region.

In addition, rising FDA approval for meningococcal vaccines is expected to boost the growth. For instance, in April 2020, Sanofi received FDA approval for its MenQuadfi Meningococcal Conjugate Vaccine for the prevention of invasive meningococcal disorders in individuals at least two years old. The increase in approval of novel vaccines is expected to improve meningococcal prevention which in turn, is anticipated to drive the market. 

Initiatives undertaken by the government to combat the rising incidence of the disease are anticipated to boost the meningococcal vaccine market growth. For instance, from April 2019, Nimenrix was made available for free as a part of the National Immunization Program (NIP) in Australia for the age group 15 to 19 years. Nimenrix is a quadrivalent meningococcal vaccine that targets serogroups A, C, W & Y. 

According to WHO, as of 2021, 24 of the 26 nations in the meningitis belt have introduced mass preventive campaigns targeting the age of 1 to 29 years. Moreover, around 13 nations have undertaken the vaccine in their national routine immunization programs. Such initiatives undertaken by countries having high disease burdens are expected to boost the market growth. 

Non-profit organizations entering into strategic initiatives such as partnering, alliances, and others to improve access to new vaccines for vulnerable children are anticipated to drive the market. For instance, in September 2021, WHO and its partners announced the first-ever global strategy to defeat meningitis. This initiative aims to reduce epidemics of bacterial meningitis. Under this strategy, WHO goals to save more than 200,000 lives annually. 

The availability of vaccines at lower prices in countries with an increasing prevalence of the meningococcal disease is anticipated to fuel the revenue of the manufacturers and drive the meningococcal vaccine market. For instance, under Meningitis Vaccine Project, MenAfriVac costs less than USD 0.5 per dose. 

 Request a free sample copy or view the report summary: Meningococcal Vaccines Market Report

Meningococcal Vaccines Market Report Highlights

• Based on type, the bivalent segment held the largest revenue share of 80.30% in 2025, due to its long-standing clinical acceptance, streamlined dosing, and continued use in routine immunization and outbreak-response settings, particularly in cost-sensitive and public procurement–driven markets.

• Based on brand, the menveo segment led the market with the largest revenue share of 29.56% in 2025, due to sustained regulatory support and product enhancements that improve usability and administration.

• Based on serotype, the Y segment led the market with the largest revenue share of 32.98% in 2025, driven by its growing association with invasive meningococcal disease among adolescents, older adults, and high-risk populations.

• Based on age group, the children and adults (2 years and above) segment led the market with the largest revenue share of 63.19% in 2025, due to its alignment with routine immunization schedules, booster policies, and risk-based vaccination strategies.

• Based on sales channels, the private segment led the market with the largest revenue share of 64.90% in 2025, due to higher vaccine uptake through private hospitals, pediatric clinics, travel medicine centers, and corporate healthcare providers.

• North America dominated the global meningococcal vaccines market with the largest revenue share of 55.16% in 2025, supported by strong regulatory oversight, high awareness, and structured immunization schedules.

Meningococcal Vaccines Market Segmentation

Grand View Research has segmented the global meningococcal vaccines market based on type, brand, serotype, age group, sales channel, and region:

Meningococcal Vaccines Type Outlook (Revenue, USD Million, 2021 - 2033)

• Bivalent

• Quadrivalent

• Others

Meningococcal Vaccines Brand Outlook (Revenue, USD Million, 2021 - 2033)

• Menactra

• Menveo

• Nimenrix

• Trumenba

• Bexsero

• Others

Meningococcal Vaccines Serotype Outlook (Revenue, USD Million, 2021 - 2033)

• A

• B

• C

• W-135

• Y

Meningococcal Vaccines Age Group Outlook (Revenue, USD Million, 2021 - 2033)

• Infants (0 to 2 years)

• Children and Adults (2 years and above)

Meningococcal Vaccines Sales Channel Outlook (Revenue, USD Million, 2021 - 2033)

• Private

• Public

Meningococcal Vaccines Regional Outlook (Revenue, USD Million, 2021 - 2033)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • Japan

  • China

  • India

  • Australia

  • South Korea

  • Thailand

• Latin America

  • Brazil

  • Argentina

• Middle East & Africa

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players in the Meningococcal Vaccines Market

• GlaxoSmithKline

• Pfizer

• Sanofi

• Merck & Co.

• Novartis

• Serum Institute of India

• Walvax Biotechnology

• Baxter International

• Bio-Med Pvt. Ltd.

• Incepta Vaccine Ltd.